8-K: Sagimet Licenses Resmetirom API for MASH Combination Therapy

Sagimet Biosciences secured a global, exclusive license from TAPI for innovative resmetirom API forms to develop a fixed-dose combination product for MASH.

Summary

• Sagimet Biosciences Inc. entered into a global, exclusive license agreement with Assia Chemical Industries Ltd. (TAPI), a subsidiary of Teva Pharmaceutical Industries Ltd.
• The agreement grants Sagimet intellectual property rights covering innovative forms of TAPI's resmetirom active pharmaceutical ingredient (API).
• The license is for Sagimet's technical evaluation, manufacture, and potential further development of a fixed-dose combination (FDC) product containing denifanstat and resmetirom.
• Sagimet previously made a non-refundable upfront payment of $2.5 million to TAPI upon execution of a term sheet.
• TAPI may be eligible to receive low single-digit royalties and potential additional manufacturing-related milestones of up to $5.5 million.
• Sagimet's Phase 1 pharmacokinetic (PK) trial of the denifanstat and resmetirom combination is currently underway, with topline data anticipated by the end of 2025.
• If Phase 1 data are positive, Sagimet plans to advance the combination for F4 MASH patients into Phase 2, estimated to start in the second half of 2026, subject to regulatory consultation.
• Sagimet anticipates selecting one of the licensed innovative forms of resmetirom for manufacturing a single FDC tablet for use in a future Phase 3 study.

Sentiment

Score: 7

Explanation: The license agreement is a positive strategic move, securing key intellectual property for a promising fixed-dose combination therapy targeting a high unmet medical need. However, clinical development is still in early stages with significant risks remaining, warranting a moderately positive sentiment.

Positives

• Secured a global, exclusive license for innovative resmetirom API forms, crucial for developing a fixed-dose combination product.
• The combination therapy targets F4-stage MASH (cirrhosis), an area with high unmet medical need and currently no approved treatment options.
• Preclinical data observed a synergistic effect of a FASN inhibitor (denifanstat) combined with resmetirom on important liver disease markers.
• Denifanstat previously demonstrated significant improvements in liver fibrosis in Phase 2b FASCINATE-2 clinical trial in MASH patients with cirrhosis.
• The FDC aims to provide a convenient, once-daily oral option that is anticipated not to require weight-based dosing, potentially improving patient adherence and outcomes.

Negatives

• A non-refundable upfront payment of $2.5 million has already been made to TAPI.
• TAPI is eligible for low single-digit royalties and potential manufacturing-related milestones of up to $5.5 million, representing future financial obligations for Sagimet.
• The combination therapy is still in early clinical development (Phase 1), with significant risks associated with clinical trial success and regulatory approval.
• There is no immediate revenue generation from this agreement; it is an investment in future pipeline development.

Risks

• The clinical development and therapeutic potential of denifanstat, TVB-3567, or any other drug candidates or combination therapies Sagimet may develop are uncertain.
• Sagimet's ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines is not guaranteed.
• The accuracy of Sagimet's estimates regarding its capital requirements may be incorrect.
• Sagimet's ability to maintain and successfully enforce adequate intellectual property protection is critical and subject to various challenges.
• Actual results could differ materially from forward-looking statements due to known and unknown risks, uncertainties, and other important factors.

Future Outlook

Sagimet plans to use the licensed innovative forms of resmetirom to develop a fixed-dose combination product with denifanstat for MASH, particularly for F4 cirrhosis patients. Topline data from the ongoing Phase 1 PK trial are expected by the end of 2025. If positive, the company anticipates advancing to Phase 2 in the second half of 2026 and eventually using a single FDC tablet in a Phase 3 study.

Management Comments

• "Our Phase 1 PK trial is an important step in the development of a new, potentially synergistic combination of denifanstat and resmetirom for the treatment of MASH. The license agreement with TAPI provides us the pathway to combine these two therapies with complementary mechanisms of action into a single once-daily tablet to improve clinical outcomes of patients who are living with cirrhosis of the liver and currently have no approved options." David Happel, CEO of Sagimet.
• "We have already initiated our evaluation of the innovative forms of resmetirom licensed to us by TAPI and intend to select one of these forms to manufacture a single tablet including denifanstat for our FDC program in MASH. We anticipate using a single FDC tablet including TAPI’s innovative form of resmetirom in our Phase 3 study, and are excited about making this convenient, once-daily oral option, which we anticipate will not require weight-based dosing, available to patients." David Happel, CEO of Sagimet.
• "We are excited to announce the license agreement with Sagimet for their FDC development program, contributing TAPI’s deep experience in the development and manufacturing of APIs. With this collaboration with Sagimet, we are excited to contribute our innovative intellectual property and manufacturing know how to Sagimet’s development of a product in an area of high medical need, cirrhosis of the liver, where there are currently no approved therapies." Dr. R. Ananthanarayanan, CEO of TAPI.

Industry Context

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive and severe liver disease affecting over 265 million people worldwide, with no approved treatments for MASH cirrhosis (F4). The development of combination therapies, especially convenient once-daily oral options, represents a significant trend in addressing complex metabolic diseases. TAPI's role as a global leader in API development and manufacturing highlights the importance of specialized expertise in bringing novel therapeutics to market.

Comparison to Industry Standards

• There are few approved treatments for non-cirrhotic MASH (F1, F2, F3 fibrosis) and no approved treatments for MASH cirrhosis (F4), positioning Sagimet's FDC program to address a critical unmet medical need.
• The goal of a convenient, once-daily oral fixed-dose combination tablet that does not require weight-based dosing could offer a significant advantage in patient adherence and market adoption compared to more complex regimens or injectable therapies in the MASH treatment landscape.

Stakeholder Impact

• Shareholders: Potential for increased company value if the fixed-dose combination therapy successfully progresses through clinical development and gains regulatory approval.
• Patients: Potential for a new, convenient, and effective treatment option for MASH cirrhosis (F4), a condition with no currently approved therapies.
• TAPI: Eligible to receive royalties and potential manufacturing-related milestones, providing a revenue stream from their intellectual property and expertise.

Next Steps

• Anticipate topline data from the Phase 1 PK trial of the denifanstat and resmetirom combination by the end of 2025.
• Evaluate and select one of the innovative forms of resmetirom licensed from TAPI for manufacturing a single FDC tablet.
• If Phase 1 data are positive, advance the combination therapy into Phase 2 development for F4 MASH patients, estimated to start in the second half of 2026, subject to regulatory consultation.
• Plan to use a single FDC tablet including TAPI's innovative form of resmetirom in a future Phase 3 study.

Key Dates

Recommendation

The license agreement for innovative resmetirom API forms is a positive strategic move, enabling Sagimet to advance its fixed-dose combination program for MASH, a disease with high unmet medical need, particularly for F4 cirrhosis patients. While the preclinical and Phase 2b data for denifanstat are encouraging, the combination therapy is still in Phase 1, and significant clinical and regulatory hurdles remain. The upfront payment and potential future milestones/royalties represent a financial commitment. Investors should hold, awaiting further clinical data and regulatory clarity before making more aggressive investment decisions.

Keywords

Sagimet Biosciences, TAPI, Resmetirom, Denifanstat, MASH, NASH, Fixed-Dose Combination, API, License Agreement, Clinical Trial, FASN Inhibitor, THR-beta Agonist, Cirrhosis, Liver Disease, Biopharmaceutical